Your browser doesn't support javascript.
loading
Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection.
Heft Neal, Molly E; Smith, Joshua D; Birkeland, Andrew C; Haring, Catherine T; Chinn, Steven B; Shuman, Andrew G; Casper, Keith A; Malloy, Kelly M; Stucken, Chaz L; Mclean, Scott A; Rosko, Andrew J; Mierzwa, Michelle L; Shah, Jennifer; Schonewolf, Caitlin; Swiecicki, Paul L; Worden, Francis P; Wolf, Gregory T; Bradford, Carol R; Prince, Mark E P; Brenner, J Chad; Spector, Matthew E.
Affiliation
  • Heft Neal ME; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Smith JD; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Birkeland AC; Department of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, California, USA.
  • Haring CT; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Chinn SB; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Shuman AG; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Casper KA; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Malloy KM; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Stucken CL; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Mclean SA; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Rosko AJ; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Mierzwa ML; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Shah J; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Schonewolf C; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Swiecicki PL; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Worden FP; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Wolf GT; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Bradford CR; Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
  • Prince MEP; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Brenner JC; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Spector ME; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Otolaryngol Head Neck Surg ; 166(3): 498-505, 2022 03.
Article in En | MEDLINE | ID: mdl-34030495
ABSTRACT

OBJECTIVE:

Bioselection to assess tumor response after induction chemotherapy has been introduced as an alternative treatment strategy to total laryngectomy for patients with advanced larynx squamous cell carcinoma (LSCC). Tumor-infiltrating lymphocytes (TILs) have proven to serve as prognostic biomarkers in head and neck cancer but have not been evaluated as a way to select patients for treatment paradigms. The aim of this study is to evaluate the role of pretreatment TILs in patients with advanced LSCC undergoing the bioselection paradigm. STUDY

DESIGN:

Retrospective study.

SETTING:

Tertiary care hospital.

METHODS:

Patients with advanced LSCC treated with bioselection and available tissue were included (N = 76). Patients were stratified into CD8-low and CD8-high cohorts by using the median TIL count. Kaplan-Meier survival analysis and multivariate cox regression were performed with SPSS version 26 (IBM).

RESULTS:

After controlling for tobacco use, tumor site, and stage, a high CD8 TIL count was an independent predictor of improved 5-year disease-specific survival (hazard ratio, 0.17 [95% CI, 0.03-0.84]; P = .03). CD8 TIL counts did not predict response to induction chemotherapy; however, subgroup analysis of patients treated with chemoradiation therapy revealed that CD8 TIL count was significantly associated with degree of response (P = .012).

CONCLUSION:

These findings support prior data published by our group showing that TILs are predictive of disease-specific survival in patients with head and neck cancer. CD8 TIL counts were significantly associated with degree of clinical response after induction chemotherapy. These results suggest that pretreatment assessment of tumor-infiltrating CD8 cells could be useful in selecting patients.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Laryngeal Neoplasms / Head and Neck Neoplasms / Larynx Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Otolaryngol Head Neck Surg Journal subject: OTORRINOLARINGOLOGIA Year: 2022 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Laryngeal Neoplasms / Head and Neck Neoplasms / Larynx Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Otolaryngol Head Neck Surg Journal subject: OTORRINOLARINGOLOGIA Year: 2022 Document type: Article Affiliation country: Estados Unidos